TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26226960
Drug: PQQ disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PQQ disodium salt (BioPQQ™) at an oral dosage of 20 mg/d for 12 weeks
Study: 26226960
Drug: PQQ disodium
Normalized name: BALSALAZIDE DISODIUM
DrugBank: Balsalazide (DB01014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PQQ disodium salt (BioPQQ™) in high LDL-chol subgroup (baseline LDL-chol ≥140 mg/dL)
Study: 20077733
Drug: JEV‐I (PHK)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JEV‐I (PHK) vaccine
Study: 20077733
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (Vero cell-derived JEV vaccine)
Study: 17275282
Drug: Dexamethasone 4
Normalized name: dexamethasone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone 4 mg and droperidol 0.625 mg (combination)
Study: 2913182
Drug: Internal Medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal Medicine Clinic
Study: 28713645
Drug: Test agent
Normalized name: Adenosine 3mg/1mL Solution for injection [Cardiac Stress Test Agent]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test agent (novel slowly dissolving adhering disc) plus oral hygiene self-care
Study: 28713645
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene self-care only
Study: 25733627
Drug: Sodium intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium intake <2300 mg/d
Study: 25733627
Drug: Increasing sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing sodium intake >2300 mg/d
Study: 22850357
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with antihypertensive treatment
Study: 22850357
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with glomerular filtration rate 60-90 ml/min per 1.73 m²
Study: 22850357
Drug: Participants with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants with glomerular filtration rate < 60 ml/min per 1.73 m²
Study: 21663813
Drug: Landiolol (0.125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Landiolol (0.125 mg/kg/min for one minute and then 0.04 mg/kg/min)
Study: 19634511
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation of clopidogrel
Study: 19634511
Drug: Reference formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference formulation of clopidogrel
Study: 16702890
Drug: Sertraline (25-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (25-200 mg/d)
Study: 16563996
Drug: Single-dose brachytherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose brachytherapy (12 Gy)
Study: 8450402
Drug: beta-carotene, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: beta-carotene, 180 mg/day
Study: 3922052
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate ointment (100 mg)
Study: 31232639
Drug: SIT (sprint
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIT (sprint interval training) - twice‐weekly all‐out effort cycle sprints consisting of 6 × 10 s sprint with 80 s recovery
Study: 29310617
Drug: Exercise group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise group (n=36): 3 weekly sessions of 35 min moderate intensity walking/running followed by 25 min resistance training
Study: 26704739
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose condition
Study: 26704739
Drug: High plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: High plasma drug levels
Study: 26704739
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual control sample (n = 128)
Study: 24907875
Drug: Ondansetron (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (8 mg, 2 mL)
Study: 24907875
Drug: Placebo (0.9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0.9% saline, 2 mL)
Study: 8179131
Drug: Pancuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancuronium 0.2 mg.kg‐1
Study: 8179131
Drug: Pipecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipecuronium 0.2 mg.kg‐1
Study: 6113682
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml saline (control)
Study: 23357152
Drug: Ferric Carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric Carboxymaltose (FCM, 500-1000 mg as single shot infusion over 20 min)
Study: 23357152
Drug: Ferric Gluconate
Normalized name: Ferric Gluconate
DrugBank: Ferrous gluconate (DB14488)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferric Gluconate (FG, 62.5 mg once weekly)
Study: 17521392
Drug: Astaxanthin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astaxanthin 40 mg daily
Study: 15496219
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg donepezil (single dose)
Study: 15496219
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg donepezil (multiple doses for 23 days)
Study: 15496219
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (5 mg donepezil, single dose)
Study: 15496219
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (5 mg donepezil, multiple doses for 23 days)
Study: 9609589
Drug: Unopposed estrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unopposed estrogen replacement therapy
Study: 9609589
Drug: Estrogen plus
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Estrogen plus progestin hormone replacement therapy
Study: 9609589
Drug: Progestin addition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin addition to estrogen therapy
Study: 7816793
Drug: Tolfenamic acid
Normalized name: Tolfenamic acid
DrugBank: Tolfenamic acid (DB09216)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolfenamic acid (200 mg t.i.d.)
Study: 7816793
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (500 mg t.i.d.)
Study: 5337269
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (green and yellow gelatin capsule filled with lactose)
Study: 5337269
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (red and white capsule containing lactose)
Study: 30566941
Drug: Ruxolitinib 20
Normalized name: ruxolitinib 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib 20 mg twice daily
Study: 24550168
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 2.5 mg/week
Study: 24550168
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 5 mg/week
Study: 24550168
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) 20 mg/week
Study: 15328178
Drug: Arzoxifene 10
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 10 mg daily
Study: 15328178
Drug: Arzoxifene 50
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 50 mg daily
Study: 10221828
Drug: sucralfate granules
Normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sucralfate granules in suspension
Study: 8174988
Drug: Intralipid 20%
Normalized name: Intralipid 20% Fat Emulsion for Injection
DrugBank: Soybean oil (DB09422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intralipid 20% (6 g/h)
Study: 23704672
Drug: Metformin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin plus intensive lifestyle intervention
Study: 1556754
Drug: Conjoint therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conjoint therapy
Study: 3890528
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg of dipyridamole for 2 weeks
Study: 25342212
Drug: Prasugrel (20/3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (20/3.75 mg, loading/maintenance dose)
Study: 23277121
Drug: Brucella melitensis
Normalized name: brucella melitensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella melitensis strain Rev. 1 vaccine (10(6) or 5 × 10(5) live cells)
Study: 23277121
Drug: Brucella melitensis
Normalized name: brucella melitensis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brucella melitensis strain Rev. 1 vaccine (7.5 × 10(6) organisms)
Study: 12375675
Drug: Diet therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet therapy and insulin as required
Study: 7579000
Drug: glipizide (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: glipizide (2.5 mg)
Study: 7579000
Drug: antipyrine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: antipyrine (20 mg/kg)
Study: 7579000
Drug: coumarin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: coumarin (5 mg)
Study: 1657526
Drug: Long-term drug
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term drug therapy (specific drug not mentioned)
Study: 27043535
Drug: EPO+G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EPO+G-CSF
Study: 25594755
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus bismuth subsalicylate
Study: 25594755
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy plus placebo
Study: 17714570
Drug: Ketamine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine with intravenous patient-controlled-analgesia morphine
Study: 10101629
Drug: Harpagophytum extract
Normalized name: Harpagophytum procumbens whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum extract WS 1531 (600 mg)
Study: 10101629
Drug: Harpagophytum extract
Normalized name: Harpagophytum procumbens whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Harpagophytum extract WS 1531 (1200 mg)
Study: 2170884
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 0.625 mg daily
Study: 2170884
Drug: Estrone sulfate
Normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estrone sulfate 1.25 mg daily
Study: 22192731
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus erlotinib
Study: 23782814
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus erlotinib (in patients with activating EGFR gene mutation)
Study: 23782814
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus placebo (in patients with activating EGFR gene mutation)
Study: 22151975
Drug: Calcium and
Normalized name: Calcium and Magnesium
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium and vitamin D supplementation (800 IU of vitamin D and 1000 mg of calcium daily)
Study: 14627173
Drug: Adjustable dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjustable dosing with budesonide/formoterol (Symbicort, Turbuhaler) 80/4.5 microg or 160/4.5 microg, two inhalations twice daily for four weeks, followed by adjustable maintenance dosing for six months
Study: 14627173
Drug: Fixed dosing
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed dosing with budesonide/formoterol (Symbicort, Turbuhaler)
Study: 9173128
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose heparin (15,000 units)
Study: 2915651
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (six cycles of cyclophosphamide 100 mg/m² orally on days 1-14, methotrexate 40 mg/m² intravenously on days 1 and 8, fluorouracil 600 mg/m² intravenously on days 1 and 8, and prednisone 40 mg/m² orally on days 1-14)
Study: 2915651
Drug: No-treatment observation
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment observation (Control)
Study: 951456
Drug: Amphetamine formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amphetamine formulations
Study: 30817402
Drug: Restrictive red
Normalized name: acid red 35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive red blood cell transfusion threshold (7 g/dl)
Study: 24983993
Drug: Onlay mesh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay mesh augmentation (OMA)
Study: 24983993
Drug: Sublay mesh
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublay mesh augmentation
Study: 19352162
Drug: Epidural lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lidocaine (10 ml, 1%)
Study: 16672092
Drug: Closed-loop group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Closed-loop group (propofol titration using a proportional differential algorithm)
Study: 16672092
Drug: Target control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target control infusion (TCI) group (manual propofol titration guided by Bispectral Index using Diprifusor device)
Study: 9143797
Drug: Daily Wear
Normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily Wear (DW)
Study: 9484362
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) during rIFN beta‐1a treatment
Study: 9484362
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (IVMP; 1 g daily for 6 days) without rIFN beta‐1a treatment
Study: 8038592
Drug: High-dose TNF
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose TNF in isolated limb perfusions
Study: 8038592
Drug: TNF, IFN,
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNF, IFN, and melphalan limb perfusion with systemic high-dose interleukin-2 postoperatively
Study: 2924980
Drug: Ketoconazole 200
Normalized name: ketoconazole 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 200 mg daily for 8 days
Study: 2924980
Drug: Terbinafine 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 500 mg daily for 8 days
Study: 241876
Drug: Propranolol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (50 mg three times daily for 4 weeks)
Study: 241876
Drug: Prindolol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prindolol (10 mg three times daily)
Study: 17932248
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate therapy
Study: 7835803
Drug: Paclitaxel plus
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel plus a platinum compound
Study: 3323072
Drug: terbutaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline (10 mg/day) and metoprolol (200 mg/day)
Study: 3323072
Drug: metoprolol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (200 mg/day) alone
Study: 3323072
Drug: terbutaline (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: terbutaline (10 mg/day) alone
Study: 23910665
Drug: Ipragliflozin 600
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 600 mg/d for 7 days
Study: 23910665
Drug: Ipragliflozin 100
Normalized name: BEXAGLIFLOZIN
DrugBank: Bexagliflozin (DB12236)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipragliflozin 100 mg/d for 7 days
Study: 21270330
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy targeting normoglycemia
Study: 16458451
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose levamisole (LMS)
Study: 11478456
Drug: Ivermectin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (100 ug/kg body weight, 2 doses, 3 months apart)
Study: 3045069
Drug: Topical therapy
Normalized name: Diclosaicin 1.5%-0.025% Topical Therapy Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy with vidarabine sodium phosphate in an aqueous gel
Study: 9703563
Drug: 1.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg/kg papaverine
Study: 8580278
Drug: 5-ASA enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-ASA enema (mesalazine 1 g/100 mL)
Study: 2293938
Drug: One-step application
Normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-step application of a water-insoluble iodophor-in-alcohol solution
Study: 33455
Drug: Thiopentone (3.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thiopentone (3.5 mg/kg)
Study: 33455
Drug: Low-dose ketamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ketamine (1 mg/kg)
Study: 27753282
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation 2
Study: 27753282
Drug: Test formulation
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test formulation 3
Study: 26083828
Drug: Aleph inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aleph inactivated split influenza vaccine
Study: 20043525
Drug: Intramuscular syntometrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular syntometrine (syntocinon 10 IU + ergometrine 0.5 mg)
Study: 17374344
Drug: Boiled extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Boiled extract of Carum copticum (0.125 ml/kg and 0.25 ml/kg)
Study: 17374344
Drug: Theophylline (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (6 mg/kg)
Study: 15596918
Drug: Chemotherapy regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy regimens in phase III clinical trials
Study: 9150013
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with nitrous/narcotic and inhalation anesthesia for maintenance
Study: 2949876
Drug: qi‐regulating; blood‐activating
Approvals — FDA: no, EMA: no, PMDA: no
Description: qi‐regulating; blood‐activating and wind‐dispelling Chinese medicine (A group, 100 cases)
Study: 2949876
Drug: cortical hormone
Normalized name: Adrenal cortical hormone-containing product
Approvals — FDA: no, EMA: no, PMDA: no
Description: cortical hormone (B group, 51 cases)
Study: 2949876
Drug: yin‐nourishing; blood‐activating
Approvals — FDA: no, EMA: no, PMDA: no
Description: yin‐nourishing; blood‐activating and wind‐dispelling Chinese medicine (C group, 53 cases)
Study: 29440005
Drug: Dapagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (10 mg·d‐1)
Study: 29440005
Drug: Bumetanide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bumetanide (1 mg·d‐1)
Study: 29440005
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Dapagliflozin and Bumetanide)
Study: 15882209
Drug: Binary system
Approvals — FDA: no, EMA: no, PMDA: no
Description: Binary system containing block copolymers as solution rinse
Study: 15882209
Drug: Ternary system
Normalized name: Prednisolone tertiary butylacetate
DrugBank: Prednisolone tebutate (DB14632)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ternary system containing block copolymers and polypeptide as solution rinse
Study: 7775634
Drug: Oxandrolone 2.5
Normalized name: oxandrolone 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone 2.5 mg daily
Study: 7775634
Drug: Testosterone 50
Normalized name: testosterone 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone 50 mg monthly IM injections
Study: 7775634
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatments (Oxandrolone and Testosterone)
Study: 2270749
Drug: Essential fatty
Normalized name: essential fatty acids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential fatty acid therapy (8 x 500 mg capsules per day for 3 months)
Study: 2270749
Drug: Placebo (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (8 x 500 mg capsules per day for 3 months)
Study: 10709150
Drug: oral verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral verapamil
Study: 9166816
Drug: Hyskon (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyskon (250 ml 32% dextran 70)
Study: 9166816
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (250 ml)
Study: 3898904
Drug: Oral hyposensitization
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral hyposensitization with timothy whole pollen (4,315,000 PNU preseasonally and 8,915,000 PNU total for 6 months)
Study: 29786336
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of 2.5-3.0 mL human umbilical cord MSCs suspension containing (2-3)×10^7 cells, once a month for 2 times
Study: 29786336
Drug: Sodium hyaluronate
Normalized name: sodium hyaluronate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium hyaluronate by intra-articular injection, once a week for 5 times
Study: 22471128
Drug: Prednisone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (10 mg orally, once daily for 2 courses)
Study: 20921898
Drug: pegylated interferon
Normalized name: Pegylated interferon alfa-2a
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pegylated interferon alfa 2a 180 mcg per week + weight-based ribavirin for 12 weeks, followed by full dose PEG for 72 weeks